Hendra Virus Vaccine, a One Health Approach to Protecting Horse, Human, and Environmental Health

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2014 Feb 28

PMID 24572697

Citations 101

Authors

Deborah Middleton

Jackie Pallister

Reuben Klein

Yan-Ru Feng

Jessica Haining

Rachel Arkinstall

Leah Frazer

Jin-An Huang

Nigel Edwards

Mark Wareing

Martin Elhay

Zia Hashmi

John Bingham

Manabu Yamada

Dayna Johnson

John White

Adam Foord

Hans G Heine

Glenn A Marsh

Christopher C Broder

Lin-Fa Wang

Affiliations

Soon will be listed here.

Abstract

In recent years, the emergence of several highly pathogenic zoonotic diseases in humans has led to a renewed emphasis on the interconnectedness of human, animal, and environmental health, otherwise known as One Health. For example, Hendra virus (HeV), a zoonotic paramyxovirus, was discovered in 1994, and since then, infections have occurred in 7 humans, each of whom had a strong epidemiologic link to similarly affected horses. As a consequence of these outbreaks, eradication of bat populations was discussed, despite their crucial environmental roles in pollination and reduction of the insect population. We describe the development and evaluation of a vaccine for horses with the potential for breaking the chain of HeV transmission from bats to horses to humans, thereby protecting horse, human, and environmental health. The HeV vaccine for horses is a key example of a One Health approach to the control of human disease.

Citing Articles

Cross-protectivity of henipavirus soluble glycoprotein in an model of Nipah virus disease.

Findlay-Wilson S, Thakur N, Crossley L, Easterbrook L, Salguero F, Ruedas-Torres I Front Immunol. 2025; 16:1517244.

PMID: 40078997 PMC: 11896980. DOI: 10.3389/fimmu.2025.1517244.

Cedar virus biology and its applications as a surrogate for highly pathogenic henipaviruses.

Sabir A, Rong L, Broder C, Amaya M Cell Insight. 2025; 3(4):100181.

PMID: 39967899 PMC: 11832809. DOI: 10.1016/j.cellin.2024.100181.

Protein Expression Platforms and the Challenges of Viral Antigen Production.

Sookhoo J, Schiffman Z, Ambagala A, Kobasa D, Pardee K, Babiuk S Vaccines (Basel). 2025; 12(12.

PMID: 39772006 PMC: 11680109. DOI: 10.3390/vaccines12121344.

Structure of the Nipah virus polymerase complex.

Balikci E, Gunl F, Carrique L, Keown J, Fodor E, Grimes J EMBO J. 2024; 44(2):563-586.

PMID: 39739115 PMC: 11730344. DOI: 10.1038/s44318-024-00321-z.

Ethics, One Health approaches, and SDGs: conference lessons for an emerging field.

Lerner H, Nordquist R, Lederman Z, Keyel J, Nickel P, Berg C Front Public Health. 2024; 12:1448409.

PMID: 39722720 PMC: 11668961. DOI: 10.3389/fpubh.2024.1448409.

References

Drexler J, Corman V, Gloza-Rausch F, Seebens A, Annan A, Ipsen A . Henipavirus RNA in African bats. PLoS One. 2009; 4(7):e6367. PMC: 2712088. DOI: 10.1371/journal.pone.0006367. View

Mahalingam S, Herrero L, Playford E, Spann K, Herring B, Rolph M . Hendra virus: an emerging paramyxovirus in Australia. Lancet Infect Dis. 2012; 12(10):799-807. DOI: 10.1016/S1473-3099(12)70158-5. View

Breed A, Yu M, Barr J, Crameri G, Thalmann C, Wang L . Prevalence of henipavirus and rubulavirus antibodies in pteropid bats, Papua New Guinea. Emerg Infect Dis. 2010; 16(12):1997-9. PMC: 3294587. DOI: 10.3201/eid1612.100879. View

Wolinsky J, Waxham M, Server A . Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis. J Virol. 1985; 53(3):727-34. PMC: 254700. DOI: 10.1128/JVI.53.3.727-734.1985. View

Plotkin S . Vaccination against the major infectious diseases. C R Acad Sci III. 2000; 322(11):943-51. DOI: 10.1016/s0764-4469(00)87191-7. View

McEachern J, Bingham J, Crameri G, Green D, Hancock T, Middleton D . A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine. 2008; 26(31):3842-52. PMC: 6186147. DOI: 10.1016/j.vaccine.2008.05.016. View

Guillaume V, Contamin H, Loth P, Georges-Courbot M, Lefeuvre A, Marianneau P . Nipah virus: vaccination and passive protection studies in a hamster model. J Virol. 2003; 78(2):834-40. PMC: 368848. DOI: 10.1128/jvi.78.2.834-840.2004. View

Williamson M, Hooper P, Selleck P, Gleeson L, Daniels P, Westbury H . Transmission studies of Hendra virus (equine morbillivirus) in fruit bats, horses and cats. Aust Vet J. 1999; 76(12):813-8. DOI: 10.1111/j.1751-0813.1998.tb12335.x. View

Mazet J, Clifford D, Coppolillo P, Deolalikar A, Erickson J, Kazwala R . A "one health" approach to address emerging zoonoses: the HALI project in Tanzania. PLoS Med. 2009; 6(12):e1000190. PMC: 2784942. DOI: 10.1371/journal.pmed.1000190. View

10.

Jones K, Patel N, Levy M, Storeygard A, Balk D, Gittleman J . Global trends in emerging infectious diseases. Nature. 2008; 451(7181):990-3. PMC: 5960580. DOI: 10.1038/nature06536. View

11.

Halpin K, Hyatt A, Fogarty R, Middleton D, Bingham J, Epstein J . Pteropid bats are confirmed as the reservoir hosts of henipaviruses: a comprehensive experimental study of virus transmission. Am J Trop Med Hyg. 2011; 85(5):946-51. PMC: 3205647. DOI: 10.4269/ajtmh.2011.10-0567. View

12.

Bossart K, Crameri G, Dimitrov A, Mungall B, Feng Y, Patch J . Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol. 2005; 79(11):6690-702. PMC: 1112112. DOI: 10.1128/JVI.79.11.6690-6702.2005. View

13.

Bossart K, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J . A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog. 2009; 5(10):e1000642. PMC: 2765826. DOI: 10.1371/journal.ppat.1000642. View

14.

Pallister J, Middleton D, Wang L, Klein R, Haining J, Robinson R . A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine. 2011; 29(34):5623-30. PMC: 3153950. DOI: 10.1016/j.vaccine.2011.06.015. View

15.

Bossart K, Geisbert T, Feldmann H, Zhu Z, Feldmann F, Geisbert J . A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med. 2011; 3(105):105ra103. PMC: 3313625. DOI: 10.1126/scitranslmed.3002901. View

16.

Mendez D, Judd J, Speare R . Unexpected result of Hendra virus outbreaks for veterinarians, Queensland, Australia. Emerg Infect Dis. 2012; 18(1):83-5. PMC: 3310112. DOI: 10.3201/eid1801.111006. View

17.

Playford E, McCall B, Smith G, Slinko V, Allen G, Smith I . Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008. Emerg Infect Dis. 2010; 16(2):219-23. PMC: 2957996. DOI: 10.3201/eid1602.090552. View

18.

Broder C, Geisbert T, Xu K, Nikolov D, Wang L, Middleton D . Immunization strategies against henipaviruses. Curr Top Microbiol Immunol. 2012; 359:197-223. PMC: 4465348. DOI: 10.1007/82_2012_213. View

19.

Marsh G, Haining J, Hancock T, Robinson R, Foord A, Barr J . Experimental infection of horses with Hendra virus/Australia/horse/2008/Redlands. Emerg Infect Dis. 2011; 17(12):2232-8. PMC: 3311212. DOI: 10.3201/eid1712.111162. View

20.

Mungall B, Middleton D, Crameri G, Bingham J, Halpin K, Russell G . Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol. 2006; 80(24):12293-302. PMC: 1676295. DOI: 10.1128/JVI.01619-06. View